New drug cocktail aims to shrink Hard-to-Treat gut tumors
NCT ID NCT05249114
First seen Apr 30, 2026 · Last updated May 22, 2026 · Updated 6 times
Summary
This early-phase study tests a new combination of two treatments—cabozantinib (a targeted drug) and radioactive Lu-177 DOTATATE—for people with advanced neuroendocrine tumors that have stopped responding to standard therapy. The main goal is to find the safest dose of cabozantinib when given with the radiation therapy. Only 6 participants are enrolled, and they continue cabozantinib long-term after the radiation cycles, so this is about controlling the disease, not curing it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Providence Portland Cancer Institute - Franz Clinic
Portland, Oregon, 97213, United States
Conditions
Explore the condition pages connected to this study.